Research programme: immune checkpoint protein inhibitors - Aurigene

Alternative Names: AUNP-12; AUR-012; NP-12 - Aurigene; PD-1 peptide antagonist - Aurigene; PDCD-1 protein inhibitors - Aurigene

Latest Information Update: 16 Jul 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Aurigene Discovery Technologies
Class Peptides
Mechanism of Action Programmed cell death 1 ligand 2 inhibitors; Programmed cell death-1 ligand-1inhibitors; Programmed cell death-1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Bacterial infections; Cancer

Most Recent Events

16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in India (Parenteral)
16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (SC)
13 Feb 2014 Aurigene and Pierre Fabre enter into a collaborative licensing, development and commercialisation agreement for AUNP 12 in Cancer

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.